Tegsedi Approved for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

The article below may contain offensive and/or incorrect content.

The approval was based on data from the Phase 3 NEURO-TTR study (N=173) which randomized patients with polyneuropathy caused by hATTR amyloidosis to Tegsedi or placebo.